Pharvaris N.V.
Business
Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare, bradykinin-mediated diseases, initially targeting hereditary and acquired angioedema. Its lead product candidate is deucrictibant, an oral small-molecule selective bradykinin B2 receptor antagonist being developed in immediate-release (on‑demand) and extended‑release (prophylactic) formulations. The company’s operations encompass clinical development, nonclinical and safety programs, manufacturing partnerships with CDMOs, intellectual property management and planned commercialization activities. Pharvaris conducts global clinical trials and intends to pursue regulatory approval and market access in the United States, Europe and other international markets.
Summary from filing dated 2025-04-07
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-175.70M |
| Total assets | $301.45M |
| Total liabilities | $30.18M |
| Stockholders' equity | — |
| Operating cash flow | — |